Efficacy of Sr-89 for Differentiated Thyroid Cancer With Bone Metastases
Status:
Not yet recruiting
Trial end date:
2025-07-13
Target enrollment:
Participant gender:
Summary
Using sensitive markers (such as thyroglobulin, etc) to evaluate the efficacy of strontium-89
chloride (Sr-89) in differentiated thyroid cancer with bone metastases with an aim to
breaking out of its palliation effect for bone pain.